tradingkey.logo
tradingkey.logo
Search

Jim Cramer Says to Buy UnitedHealth Group Stock. Is He Right?

The Motley FoolJun 24, 2026 12:20 PM
facebooktwitterlinkedin
View all comments0

Key Points

  • UnitedHealth Group's stock price has jumped almost 40% in the past two months.

  • Is Cramer right about UnitedHealth?

After falling to $255 per share in late March, UnitedHealth Group (NYSE: UNH) stock has been on a heater. The leading health insurer has skyrocketed some 57% since March 30 and is currently trading at $408 per share. It went from being down 22% year to date as of March 30 to being up 24% year to date as of June 22.

The major catalyst for the recent spike is a move by the Centers for Medicare & Medicaid Services (CMS) to raise Medicare Advantage insurers' rates by 2.48% in 2027.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

And Jim Cramer, host of CNBC's Mad Money, thinks it has more room to run. He said on his show recently:

Finally, we have UnitedHealth. It's another managed care play that's up for the same reason as Humana. The stock pulled back this afternoon, but the legendary CEO, Steve Hemsley, is back, and he's so good. A brutal stint of bad management before he got there. He's turning it around. UnitedHealth, buy it.

A doctor looking at a chart with healthcare professionals in the background.

Image source: Getty Images.

Cramer also called UnitedHealth a "textbook safety stock." Is he right?

UNH is still a bargain

The Mad Money host is absolutely on the money with this call. UnitedHealth stock is still a bargain, even after its recent surge.

While its valuation has crept up, it is still trading at just 21 times forward earnings. That's because it's still down considerably from the near-$600-per-share price it hit just over a year ago in April 2025, before the tariff crash.

It may not return to $600 anytime soon, but 77% of Wall Street analysts rate it a buy, with a median price target of $420 per share.

Here are four quick reasons why UnitedHealth stock is a buy:

  1. It smashed earnings estimates last quarter.
  2. It raised its 2026 earnings guidance.
  3. It's got a high yield and a consistent dividend.
  4. As a major healthcare stock, it tends to perform well in market downturns, making it a great defensive play.

Should you buy stock in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $393,037!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,280,627!*

Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 24, 2026.

Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.